Centene Corporation announced that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Centene's proposed acquisition of substantially all of the assets of Fidelis Care for $3.75 billion. As previously announced on September 12, 2017, the acquisition of the assets of Fidelis Care will expand Centene's national leadership in government sponsored healthcare with a leadership position in New York. The transaction is expected to close in the first quarter of 2018, subject to various closing conditions and receipt of New York regulatory approvals, including approvals under the New York Not-for-Profit Corporation Law.